Skip to main content
. 2020 Jul 27;6(7):e04321. doi: 10.1016/j.heliyon.2020.e04321

Table 2.

Dentists' answer to the question “MRONJ risk among osteoporosis patients is related to…”.

Dentist's answer Frequency Percent Cumulative Percent
Oral alendronate (Fosamax®) for 1 year 3 4.1 4.1
Oral sorafenib (Nexavar®) for 2 months 3 4.1 8.1
Long term oral bisphosphonate greater than 4 years or IV zoledronate 14 18.9 27.0
Oral ibandronate (Boniva®) 3 4.1 31.1
Not aware 51 68.9 100.0
Total 74 100.0